The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Open accessAbstract
BACKGROUND: Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resection with macroscopic tumor clearance. There is a strong rationale for a neoadjuvant approach, since a relevant percentage of pancreatic cancer patients present with non-metastatic but locally advanced disease and microscopic incomplete resections are common. The objective of the present analysis was to systematically review studies concerning the effects of neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer. METHODS AND FINDINGS: Trials were identified by searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1966 to December 2009 as well as through reference lists of articles and proceedings of major meetings. Retrospective and prospective studies analyzing neoadjuvant radiochemotherapy, radiotherapy, or chemotherapy of pancreatic cancer patients, followed by re-staging, and surgical exploration/resection were included. Two reviewers independently extracted data and assessed study quality. Pooled relative risks and 95% confidence intervals were calculated using random-effects models. Primary outcome measures were proportions of tumor response categories and percentages of exploration and resection. A total of 111 studies (n = 4,394) including 56 phase I-II trials were analyzed. A median of 31 (interquartile range [IQR] 19-46) patients per study were included. Studies were subdivided into surveys considering initially resectable tumors (group 1) and initially non-resectable (borderline resectable/unresectable) tumors (group 2). Neoadjuvant chemotherapy was given in 96.4% of the studies with the main agents gemcitabine, 5-FU (and oral analogues), mitomycin C, and platinum compounds. Neoadjuvant radiotherapy was applied in 93.7% of the studies with doses ranging from 24 to 63 Gy. Averaged complete/partial response probabilities were 3.6% (95% CI 2%-5.5%)/30.6% (95% CI 20.7%-41.4%) and 4.8% (95% CI 3.5%-6.4%)/30.2% (95% CI 24.5%-36.3%) for groups 1 and 2, respectively; whereas progressive disease fraction was estimated to 20.9% (95% CI 16.9%-25.3%) and 20.8% (95% CI 14.5%-27.8%). In group 1, resectability was estimated to 73.6% (95% CI 65.9%-80.6%) compared to 33.2% (95% CI 25.8%-41.1%) in group 2. Higher resection-associated morbidity and mortality rates were observed in group 2 versus group 1 (26.7%, 95% CI 20.7%-33.3% versus 39.1%, 95% CI 29.5%-49.1%; and 3.9%, 95% CI 2.2%-6% versus 7.1%, 95% CI 5.1%-9.5%). Combination chemotherapies resulted in higher estimated response and resection probabilities for patients with initially non-resectable tumors ("non-resectable tumor patients") compared to monotherapy. Estimated median survival following resection was 23.3 (range 12-54) mo for group 1 and 20.5 (range 9-62) mo for group 2 patients. CONCLUSIONS: In patients with initially resectable tumors ("resectable tumor patients"), resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy. Approximately one-third of initially staged non-resectable tumor patients would be expected to have resectable tumors following neoadjuvant therapy, with comparable survival as initially resectable tumor patients. Thus, patients with locally non-resectable tumors should be included in neoadjuvant protocols and subsequently re-evaluated for resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Although no randomized phase III trials could be considered within this review, general recommendations from QUOROM [26] and the PRISMA revision [27] with regard to processing and reporting of results were taken into account (Text S1).”
BackgroundPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Hospital Volume and Surgical Mortality in the United States
Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V. A., Stukel, T. A., Lucas, F. L., Batista, I., Welch, H. G., & Wennberg, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012337 · Cited by 4,999
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationTransformations Related to the Angular and the Square Root
Freeman, M. F., & Tukey, J. W. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729756 · Cited by 2,628
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Wilkinson, E. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00737-4 · Cited by 951
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., et al. (2008) · JAMA · doi:10.1001/jama.299.9.1019 · Cited by 755
Gastrointestinal Tumor Study Group (1987) · Cancer · doi:10.1002/1097-0142(19870615)59:12<2006::aid-cncr2820591206>3.0.co;2-b · Cited by 714
Most Pancreatic Cancer Resections are R1 Resections
Esposito, I., Kleeff, J., Bergmann, F., Reiser, C., Herpel, E., Friess, H., Schirmacher, P., & Büchler, M. W. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9839-8 · Cited by 645
Self-citationStudy Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Changes in Morbidity After Pancreatic Resection: Toward the End of Completion Pancreatectomy
Büchler, M. W. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.12.1310 · Cited by 604
Redefining the R1 resection in pancreatic cancer
Verbeke, C. S., Leitch, D., Menon, K. V., McMahon, M. J., Guillou, P. J., & Anthoney, A. (2006) · British Journal of Surgery · doi:10.1002/bjs.5397 · Cited by 593
National Failure to Operate on Early Stage Pancreatic Cancer
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Stewart, A. K., Winchester, D. P., & Talamonti, M. S. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180691579 · Cited by 554
The Inverse of the Freeman – Tukey Double Arcsine Transformation
Miller, J. J. (1978) · The American Statistician · doi:10.1080/00031305.1978.10479283 · Cited by 535
Preoperative Staging and Assessment of Resectability of Pancreatic Cancer
Warshaw, A. L. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410140108018 · Cited by 471
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Bakkevold, K. E., Arnesjø, B., Dahl, O., & Kambestad, B. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80349-1 · Cited by 338
Michalski, C. W., Kleeff, J., Wente, M. N., Diener, M. K., Büchler, M. W., & Friess, H. (2007) · British Journal of Surgery · doi:10.1002/bjs.5716 · Cited by 302
Self-citationLaethem, J. V., Hammel, P. R., Mornex, F., Azria, D., van Tienhoven, G., Vergauwe, P. L., Peeters, M., Polus, M., Praet, M., Mauer, M. E. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3446 · Cited by 299
Surgery for Recurrent Pancreatic Ductal Adenocarcinoma
Kleeff, J., Reiser, C., Hinz, U., Bachmann, J., Debus, J., Jaeger, D., Friess, H., & Büchler, M. W. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000245845.06772.7d · Cited by 249
Self-citationSiriwardana, H. P. P., & Siriwardena, A. K. (2006) · British journal of surgery · doi:10.1002/bjs.5368 · Cited by 242
Multivisceral Resection for Pancreatic Malignancies: Risk-Analysis and Long-Term Outcome
Hartwig, W., Hackert, T., Hinz, U., Hassenpflug, M., Strobel, O., Büchler, M. W., & Werner, J. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181ad657b · Cited by 207
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
(2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0035 · Cited by 181
S3-Leitlinie „Exokrines Pankreaskarzinom” 2007
Adler, G., Seufferlein, T., Bischoff, S., Brambs, H. –., Feuerbach, S., Grabenbauer, G. G., Hahn, S. A., Heinemann, V., Hohenberger, W., Langrehr, J. M., et al. (2007) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2007-963224 · Cited by 174
Gaedcke, J., Gunawan, B., Grade, M., Szöke, R., Liersch, T., Heinz Becker, A., & Ghadimi, Β. M. (2009) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-009-0494-8 · Cited by 143
Controversies in meta-analysis: the case of the trials of serum cholesterol reduction
Thompson, S. G. (1993) · Statistical Methods in Medical Research · doi:10.1177/096228029300200205 · Cited by 118
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604436 · Cited by 104
An evaluation of the Vincentizing method of forming group-level response time distributions
Rouder, J. N., & Speckman, P. L. (2004) · Psychonomic Bulletin & Review · doi:10.3758/bf03196589 · Cited by 75
Wolff, R. A., Varadhachary, G. R., & Evans, D. B. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0002-3 · Cited by 65
Cited by
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Self-citationLi, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,719
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Metadata
- Authors
- Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-04-20
- Volume
- 7
- Issue
- 4
- Pages
- e1000267
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W1994177577
- Cited by
- 1,552
- References
- 38
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.